The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.

Unlike combinational power reduction tools, PowerPro CG identifies and generates sequential clock-gating transformations. It fits into existing design flows with industry-standard library, timing, and ...